Aurobindo Pharma Q2FY19 Result Expectation

Aurobindo Pharma is expected to report a 5.7 percent YoY revenue growth over new product launches; profitability is likely to remain weak due to high base.

Consensus estimates for Q2FY19

• Revenue– ₹4691 crore, up 5.7 percent YoY, due to weak currency, lower base price erosion, and market share gain in gIbuprofen, gReyataz, and gErtapenem.
• EBITDA – Expected to decline 11.6 percent YoY to ₹988 crore due to high base; EBITDA margin expected at 21.1 percent.
• PAT – Expected to decline 17.3 percent YoY to ₹606 crore.

Q1FY19 performance highlights

• Revenue – ₹3 crore grew 15.5 percent YoY.
• EBITDA – ₹1 crore, declined 14.7 percent YoY, margins stood at 16.7 percent.
• PAT – ₹7 crore, YoY decline of 12.1 percent. – India Infoline